Drug and Medical Device Litigation Law Blog

Seroquel Lawsuits Sent Back To Home States

Thursday, November 19, 2009 by Brett A. Emison

Learn how to protect yourself against dangerous drugs at our web site.... Read More
Posted at 10:20 AM  |  PERMALINK
Topic: Drug and Medical Device Litigation

Yaz Side Effects: FDA Warning Letters

Wednesday, November 18, 2009 by Brett A. Emison

Learn more about Yaz and Yasmin side effects and what you can do to if you have taken these birth control pills.

... Read More
Posted at 14:52 PM  |  PERMALINK
Topic: Drug and Medical Device Litigation

Yaz Side Effects: Protect Yourself

Wednesday, November 18, 2009 by Brett A. Emison

Popular birth control pills, Yaz, Yasmin and Ocella, have been linked to serious and potentially deadly side effects. This deadly side effects affect women of all ages, including teens and young women.... Read More
Posted at 14:51 PM  |  PERMALINK
Topic: Drug and Medical Device Litigation

Consumers Union's Safe Patient Project Forum Webcast: "To Err Is Human, To Delay Is Deadly"

Wednesday, November 18, 2009 by Thomas J. Lamb

Marks 10th Anniversary Of IOM Study On Medical Errors And Raises Concerns About Lack Of Progress... Read More
Posted at 08:39 AM  |  PERMALINK
Topic: Drug and Medical Device Litigation

AstraZeneca Paid To Promote Seroquel Despite Concerns

Tuesday, November 17, 2009 by Brett A. Emison

The Chicago Tribune recently reported on the millions that foreign drug maker AstraZeneca paid doctors to promote its anti-psychotic drug, Seroquel, despite doctors' concerns about Seroquel side effects.  Learn how to protect yourself against dangerous drugs at our Read More

Posted at 11:10 AM  |  PERMALINK
Topic: Drug and Medical Device Litigation

Eli Lilly To Pay $24 Million In Utah Zyprexa Settlement

Thursday, November 12, 2009 by Brett A. Emison

The Deseret News has reported that pharmaceutical company, Eli Lilly, will pay the state of Utah $24 million to settle a lawsuit over Lilly's anti-psychotic drug, Zyprexa.  You can learn more about dangerous drugs and how to protect yourself at our pharmaceutical ... Read More
Posted at 12:30 PM  |  PERMALINK
Topic: Drug and Medical Device Litigation

Report: Pfizer Made Misleading Studies On Neurontin

Thursday, November 12, 2009 by Brett A. Emison

USA Today has reported that a recent study suggests Pfizer mislead regulators and the public by filing misleading reports about its epilepsy drug, Neurontin. 

You can learn more about dangerous drugs and how to protect yourself at our pharmaceutical safety blog or by visitin... Read More

Posted at 08:21 AM  |  PERMALINK
Topic: Drug and Medical Device Litigation

Anemia Drugs Procrit And Aranesp May Increase Twofold The Risk Of Potentially Fatal Blood Clots

Thursday, November 12, 2009 by Thomas J. Lamb

Results From Large Long-Term Study Show Association Between These Erythropoiesis-Stimulating Agents And Venous Thromboembolism... Read More
Posted at 08:20 AM  |  PERMALINK
Topic: Drug and Medical Device Litigation

Aranesp Associated With Increased Risk For Stroke In Patients With Diabetes And Chronic Kidney Disease

Monday, November 9, 2009 by Thomas J. Lamb

TREAT Study Revealed, Also, That This Amgen Anemia Drug Was No Better Than Placebo In Reducing Deaths Or Cardiovascular Problems... Read More
Posted at 08:17 AM  |  PERMALINK
Topic: Drug and Medical Device Litigation

Seroquel Settlement - AstraZeneca Pays More Than $500 Million To Settle Four Seroquel Lawsuits

Friday, October 30, 2009 by Brett A. Emison

The New York Times reported that AstraZeneca -- the manufacturer of the atypical antipsychotic drug, Seroquel -- will pay $520 million to settle two federal investigations and two whistle-blower lawsuits.  Learn more here.

... Read More
Posted at 15:00 PM  |  PERMALINK
Topic: Drug and Medical Device Litigation
« previous page   (Page 1 of 6, totaling 58 entries)   next page »
Lawyers.com Blog

Lawyers.comSM Blog

Get an inside view of
Lawyers.com

Blog Topics

  • Drug and Medical Device Litigation (58)

Bloggers

Archives

Recent...



Terms & Conditions   Privacy   Copyright © 2009 LexisNexis, a division of Reed Elsevier Inc. All rights reserved.